Latest news
Loading news…
Ambit Biosciences, a biopharmaceutical company, develops small molecule kinase inhibitors for cancer and inflammatory disease treatments.
Ambit Biosciences was acquired by Daiichi Sankyo in 2014 for $410M.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Investments
1
Monthly Visits
Available in Pro Contacts
35
Patents
53
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 4
- Patents granted
- 53
- Trademarks
- 0
- Top patent class
- Medical Or Veterinary Science; Hygiene
- IT spend
- $557.89K
Investor Activity
- Investments
- 1
- Portfolio orgs
- 1
Company Info
- Org types
- company, investor
- HQ
- San Diego, California, United States
Signals & Scores
- Trend (7d)
- -0.2
- Trend (30d)
- 6.5
- Trend (90d)
- 0
Investments by Ambit Biosciences
Loading columns…
0 of 0Show
Page 1 / 1
Key People at Ambit Biosciences
President & CEO
35
professional contacts at Ambit Biosciences
Contact execs at Ambit Biosciences →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Ambit Biosciences
Loading news…
FAQs about Ambit Biosciences
People who checked this page also checked these
Browse the full Acquirezy directory.